Search Tag: ARDS
2024 09 Apr
The heterogeneity of acute respiratory distress syndrome (ARDS) has played a role in hindering successful pharmacotherapy in clinical trials. To address this, researchers have identified two molecular phenotypes of ARDS - hypoinflammatory and hyperinflammatory - through latent class analysis (LCA) applied to protein biomarkers and clinical data...Read more
2024 28 Feb
Acute respiratory distress syndrome (ARDS) poses a significant global health challenge, with high in-hospital mortality rates of approximately 40% despite advancements in supportive care. There's notable variability in patient management across different regions, with proven life-saving treatments like low tidal volume ventilation not uniformly...Read more
2024 13 Feb
Cell-based therapies, particularly mesenchymal stromal cells (MSCs), hold significant promise for treating acute respiratory distress syndrome (ARDS). MSCs exhibit therapeutic effects such as reducing inflammation, improving lung function, and promoting tissue repair. These cells can be sourced from different tissues, affecting their ease of harvest...Read more
2023 06 Dec
ARDS is a life-threatening respiratory failure characterised by acute hypoxaemia and bilateral radiographic infiltrates. The definition of ARDS has evolved over 50 years, with recent suggestions to include intubated and non-intubated patients. Management remains largely supportive, focusing on strategies to limit lung injury, but high mortality rates...Read more
2023 08 Nov
Acute Respiratory Distress Syndrome (ARDS) has been known for over a century but was officially described in 1967. Despite revisions in its definition, there's ongoing debate about whether ARDS is a distinct medical condition. The current diagnostic criteria for ARDS are challenging to apply in clinical practice, so standardising the assessment of...Read more
2023 13 Oct
Mechanical power is an easy bedside tool to guide lung protective ventilation, as it is an index of the energy load applied to the lung during mechanical ventilation and expresses in one formula all the main determinants of ventilator-induced lung injury. Although a threshold value has not already been defined, a mechanical power greater than 17...Read more
2023 18 Jul
A new study aimed to evaluate the effectiveness of ventilation with ultra-low tidal volume (ULTV) compared to low tidal volume (LTV) in patients suffering from COVID-19-related acute respiratory distress syndrome (ARDS). COVID-19-related ARDS is associated with a high mortality rate and extended mechanical ventilation duration. The study...Read more
2023 05 Apr
Acute respiratory distress syndrome (ARDS) is a frequently observed condition in mechanically ventilated patients in ICUs and is associated with a high mortality rate. The presence of shock in ARDS indicates poor prognosis, with echocardiography studies suggesting that right ventricular dysfunction (RVD) plays a significant role in the cardiovascular...Read more
2023 13 Mar
Despite several biomarkers having been studied for diagnosis and/or prognosis of acute respiratory distress syndrome (ARDS), their extensive use has not been established. Better knowledge of the pathophysiology of ARDS and acute lung injury (ALI) may help develop new biomarkers. Acute respiratory distress syndrome (ARDS) is characterised by...Read more
2023 15 Feb
Prone positioning is a medical intervention that was initially proposed over 50 years ago as a way to improve gas exchange. Multiple clinical trials have been conducted on its effectiveness, with the Proning Severe ARDS Patients landmark trial demonstrating a mortality benefit in patients with severe ARDS. As a result, expert consensus and societal...Read more
2023 15 Feb
There is increasing evidence supporting the use of extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome (ARDS) in patients that do not respond to maximal medical therapy. ARDS can occur in some COVID-19 patients who are hospitalised, and ECMO can be utilised as a treatment option in some cases. Using ECMO can help...Read more
2022 08 Dec
Imaging is integral to managing critically ill patients in the ICU as it is a key source of diagnostic information to guide clinical decision-making. In recent years, there has been significant evolution in the field of critical care imaging with an increased focus on improving imaging modalities and methodologies and increasing access to imaging...Read more
2022 08 Dec
Computed tomography (CT) remains an invaluable technique to evaluate lung morphology and response to ventilatory strategy and to understand the pathophysiology of Acute Respiratory Distress Syndrome (ARDS) patients. The first report of Acute Respiratory Distress Syndrome (ARDS) in 1967 described patients with severe hypoxaemia and bilateral...Read more
2022 12 Jul
COVID-19 has resulted in an estimated 270,000 hospitalisations in ICUs in Europe between May 2020 and March 2022. Nearly 80% of these patients have required tracheal intubation and invasive mechanical ventilation. While there is still an ongoing debate whether acute respiratory distress syndrome (ARDS) physiopathology is the same in COVID-19 and non-COVID-19...Read more
2022 05 Jul
There have been conflicting results concerning lung recruitability of COVID-19 acute respiratory distress syndrome (ARDS) and the use of techniques derived from changes in respiratory mechanics and/or gas exchange in response to positive end-expiratory pressure (PEEP) increase. Various factors may explain the heterogeneity of reports regarding recruitability...Read more
2022 27 Apr
COVID-19 has resulted in the death of over 4 million people worldwide. In severe cases of COVID-19, acute respiratory infection leads to severe pneumonia, which worries to progress hypoxaemia and acute respiratory distress syndrome (ARDS). Prolonged sessions in the prone position is an effective intervention to decrease mortality in these patients....Read more
2022 28 Apr
Speakers Thomas Metkus, MD Divisions of Cardiology and Cardiac Surgery, Departments of Medicine and Surgery Johns Hopkins University School of Medicine Dennis Begos, MD, FACS, FACRS Medical Director, Medical and Scientific Affairs...Read more
2022 08 Mar
Many patients with COVID-19-associated acute respiratory failure fulfil the criteria of acute respiratory distress syndrome (ARDS) and require invasive mechanical ventilation. Therefore, it is important to understand the features of gas exchange abnormalities, respiratory mechanics and lung recruitability in these patients to provide an appropriate...Read more
2022 01 Mar
Approximately 2-4% of patients admitted to PICUs suffer from paediatric acute respiratory distress syndrome (PARDS). PARDS has a mortality rate of nearly 20% and has no specific treatment. Identifying children at risk of developing PARDS could potentially result in more targeted therapies to prevent disease progression and improve patient outcomes. ...Read more
2022 25 Jan
An observational, multicohort, retrospective study was conducted to validate two machine-learning clinical classifier models for assigning acute respiratory distress syndrome (ARDS) subphenotypes. Two ARDS subphenotypes with distinct biological and clinical features and differential treatment responses have been identified in seven individual cohorts....Read more
2021 14 Dec
Acute Respiratory Distress Syndrome (ARDS) was described as a syndrome in 1967. At that time, it was defined as a condition characterised by severe hypoxaemia and diffuse bilateral opacities. Diagnosis of ARDS has always been context-dependent, but overall, achievements in traumatic and medical resuscitation and the use of invasive mechanical ventilation...Read more
2021 02 Nov
Acute Respiratory Distress Syndrome (ARDS) is a potentially fatal condition characterised by acute hypoxaemia, and bilateral radiographic infiltrates and a mortality of 36 to 47%. Interventions like lung protective ventilation (LPV) and prone positioning have been shown to improve survival but remain underused. Other treatment methods such as neuromuscular...Read more
2021 19 Oct
Patients with COVID-19 related ARDS present with distinct respiratory subphenotypes. But most phenotyping schema is limited by sample size, disregard for temporal dynamics and insufficient validation. In the PRoVENT-COVID study, researchers aimed to identify respiratory subphenotypes of COVID-19-related ARDS. This was an investigator-initiated...Read more
2021 14 Sep
Acute respiratory distress syndrome (ARDS) occurs in approximately 40% of patients with severe acute brain injury (sABI), including acute ischaemic stroke, subarachnoid haemorrhage, intracerebral haemorrhage and traumatic brain injury. It is also a major determinant of morbidity and mortality. With the increase in ARDS cases and reports of neurological...Read more
2021 01 Sep
Acute hypoxaemic respiratory failure is a leading cause of admission to ICUs and is associated with significant mortality and morbidity. Many patients affected by acute hypoxaemic respiratory failure meet the diagnostic criteria for acute respiratory distress syndrome. An important intervention that has been shown to reduce mortality in patients with...Read more
2021 23 Aug
Mortality in patients with COVID-19 is much higher in patients who need invasive ventilation for acute respiratory distress syndrome (ARDS). COVID-19 patients with ARDS are a heterogeneous group with diverse evolutions that could be due to different phenotypes and response to care, including invasive ventilation strategies. The Practice of VENTilation...Read more
2021 17 Aug
There is sufficient evidence to show that prone positioning improves oxygenation and respiratory mechanics and is also associated with lower mortality in patients with moderate to severe ARDS. However, some patients can develop refractory hypoxaemia and hypercapnia that could require the use of venovenous extracorporeal membrane oxygenation (VV-ECMO)...Read more
2021 20 Jul
ARDS is a heterogeneous syndrome rather than a distinct disease. It is this heterogeneity that often makes it difficult to study treatments for patients with ARDS. Literature on ARDS is rife with clinical trials that do not show any mortality benefit. Recent evidence suggests different sub-phenotypes within the heterogeneous patient population....Read more